|
1
|
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
|
N Engl J Med
|
2009
|
3.85
|
|
2
|
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
|
Nat Genet
|
2013
|
3.19
|
|
3
|
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.
|
Cancer Cell
|
2009
|
2.73
|
|
4
|
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.
|
Mol Cell Biol
|
2009
|
2.06
|
|
5
|
Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells.
|
Cancer Cell
|
2008
|
1.86
|
|
6
|
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
|
Neuro Oncol
|
2011
|
1.80
|
|
7
|
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
|
Mol Cell Biol
|
2009
|
1.78
|
|
8
|
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.
|
Am J Med Genet A
|
2013
|
1.72
|
|
9
|
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.
|
Cancer Res
|
2007
|
1.60
|
|
10
|
Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas.
|
Brain Pathol
|
2008
|
1.59
|
|
11
|
miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways.
|
Cancer Res
|
2010
|
1.54
|
|
12
|
Histology-based expression profiling yields novel prognostic markers in human glioblastoma.
|
J Neuropathol Exp Neurol
|
2005
|
1.34
|
|
13
|
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
|
Am J Med Genet A
|
2011
|
1.24
|
|
14
|
YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.
|
Clin Cancer Res
|
2005
|
1.23
|
|
15
|
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
|
Neuro Oncol
|
2013
|
1.16
|
|
16
|
Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
|
Mol Ther
|
2011
|
1.04
|
|
17
|
Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.
|
Neoplasia
|
2008
|
1.03
|
|
18
|
Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms.
|
Int J Cancer
|
2003
|
1.02
|
|
19
|
Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
|
Mol Cancer Res
|
2012
|
0.98
|
|
20
|
Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation.
|
Cancer Res
|
2011
|
0.98
|
|
21
|
Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma.
|
Cancer Genet Cytogenet
|
2005
|
0.96
|
|
22
|
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.
|
Neurobiol Dis
|
2007
|
0.94
|
|
23
|
Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.
|
J Proteome Res
|
2010
|
0.91
|
|
24
|
Genetic determinants of hearing loss associated with vestibular schwannomas.
|
Otol Neurotol
|
2009
|
0.88
|
|
25
|
A novel imaging-compatible sciatic nerve schwannoma model.
|
J Neurosci Methods
|
2010
|
0.88
|
|
26
|
Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
|
Brain Pathol
|
2007
|
0.88
|
|
27
|
A role for the p53 pathway in the pathology of meningiomas with NF2 loss.
|
J Neurooncol
|
2008
|
0.88
|
|
28
|
Insights into meningioangiomatosis with and without meningioma: a clinicopathologic and genetic series of 24 cases with review of the literature.
|
Brain Pathol
|
2005
|
0.84
|
|
29
|
Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.
|
Acta Neuropathol Commun
|
2014
|
0.84
|
|
30
|
Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging.
|
Clin Cancer Res
|
2011
|
0.84
|
|
31
|
Ependymoma of the sella turcica: a variant of pituicytoma.
|
Hum Pathol
|
2008
|
0.83
|
|
32
|
Nf1 loss and Ras hyperactivation in oligodendrocytes induce NOS-driven defects in myelin and vasculature.
|
Cell Rep
|
2013
|
0.81
|
|
33
|
Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas.
|
Neuropathology
|
2012
|
0.80
|
|
34
|
An intraoperative multimodal neurophysiologic approach to successful resection of precentral gyrus epileptogenic lesions.
|
Epilepsia
|
2012
|
0.78
|
|
35
|
Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas.
|
J Neuropathol Exp Neurol
|
2008
|
0.78
|
|
36
|
Update from the 2013 International Neurofibromatosis Conference.
|
Am J Med Genet A
|
2014
|
0.78
|
|
37
|
Superficial neurofibromas in the setting of schwannomatosis: nosologic implications.
|
Acta Neuropathol
|
2010
|
0.76
|
|
38
|
Decreased vision and junctional scotoma from pituicytoma.
|
Case Rep Ophthalmol
|
2012
|
0.75
|